CAR-T Followed by Bispecific Antibodies

NCT04889716 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Large B-cell Lymphoma
DLBCL - Diffuse Large B Cell Lymphoma

Interventions

DRUG: mosunetuzumab
DRUG: glofitamab
DRUG: obinutuzumab

Sponsor

Abramson Cancer Center at Penn Medicine

Collaborators

[object Object]